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Abstract
In patients, chronic treatment with lithium leads to renal microcysts and
nephrogenic diabetes insipidus (NDI). It was hypothesized that renal cyclooxy-
genase-2 (COX-2) activity promotes microcyst formation and NDI. Kidney
microcysts were induced in male adolescent rats by feeding dams with lithium
(50 mmol/kg chow) from postnatal days 7–34. Lithium treatment induced
somatic growth retardation, renal microcysts and dilatations in cortical collect-
ing duct; it increased cortical cell proliferation and inactive pGSK-3b abun-
dance; it lowered aquaporin-2 (AQP2) protein abundance and induced
polyuria with decreased ability to concentrate the urine; and it increased COX-
2 protein level in thick ascending limb. Concomitant treatment with lithium
and a specific COX-2 inhibitor, parecoxib (5 mg/kg per day, P10–P34), did
not prevent lithium-induced microcysts and polyuria, but improved urine
concentrating ability transiently after a 1-desamino-8-D-arginine vasopressin
challenge. COX-2 inhibition did not reduce cortical lithium-induced cell
proliferation and phosphorylation of glycogen synthase kinase-3b (GSK-3b).
COX-1 protein abundance increased in rat kidney cortex in response to
lithium. COX-1 immunoreactivity was found in microcyst epithelium in rat
kidney. A human nephrectomy specimen from a patient treated for 28 years
with lithium displayed multiple, COX-1-immunopositive, microcysts. In
chronic lithium-treated adolescent rats, COX-2 is not colocalized with micro-
cystic epithelium, mitotic activity, and inactive pGSK-3b in collecting duct; a
blocker of COX-2 does not prevent cell proliferation, cyst formation, or GSK-
3b inactivation. It is concluded that COX-2 activity is not the primary cause
for microcysts and polyuria in a NaCl-substituted rat model of lithium
nephropathy. COX-1 is a relevant candidate to affect the injured epithelium.
Introduction
Lithium has been used for decades to treat patients with
bipolar affective disorder. Treatment causes a range of
renal adverse effects: polyuria, microcysts, and, more
infrequently, a decrease in glomerular filtration rate
(GFR) and renal fibrosis (Hestbech et al. 1977; Boton
et al. 1987; Farres et al. 2003). Data from our laboratory
have shown that the postnatal period in rats around
weaning constitutes a sensitive “window” compared to
adult kidney, where lithium treatment precipitates signifi-
cant morphological alterations with cortical epithelial pro-
liferation and microcysts that resemble the human
counterpart (Kjaersgaard et al. 2011). Glycogen synthase
kinase-3b (GSK-3b) is a known target of lithium (Klein
and Melton 1996; Stambolic et al. 1996), and lithium-
induced microcysts are GSK-3b positive and the cyst epi-
thelium is proliferative. Lithium treatment in rodents, like
in patients, leads to polyuria (Christensen et al. 1982; Rao
et al. 2005). The question then arises whether the
observed cysts are directly mediated by lithium in target
cells or induced secondarily by, for example, paracrine
mediators and/or the accompanying polyuria. Prostaglan-
dins are thought to promote cyst growth in polycystic
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kidney disease and in the rat kidney cyclooxygenase-2
(COX-2) is expressed in cells of the thick ascending limb
of Henles loop (TAL) and in the macula densa in cortex
and in medullary interstitial cells (Harris et al. 1994). The
main product of COX-2 in the kidneys is prostaglandin
E2 (PGE2), which is known to promote salt and water
excretion after lithium (Bonvalet et al. 1987; Breyer and
Breyer 2000). Casuistic reports show that lithium-induced
nephrogenic diabetes insipidus (NDI) can be attenuated
by nonsteroidal antiinflammatory drugs (NSAIDs), which
are COX inhibitors, in patients (Lam and Kjellstrand
1997). In animal models of NDI induced by lithium,
increased expression of COX-2 and elevated urinary
excretion of PGE2 has been shown (Kotnik et al. 2005;
Rao et al. 2005). Inhibition of COX-2 attenuates lithium-
induced polyuria in adult mice and rats (Sugawara et al.
1988; Kim et al. 2008). Mice lacking prostaglandin E2
synthase-1 (mPGES-1) are resistant to lithium-induced
polyuria (Jia et al. 2009). It is therefore possible that
COX-2/PGE-S/PGE2-driven polyuria contributes to the
development of microcysts. Because increased flow per se
is not typically associated with microcysts, a direct effect
of lithium on the epithelium which could be amplified by
prostaglandins is also possible. Lithium decreases GSK-3b
enzyme activity by phosphorylation at the serine 9 residue
(Sutherland et al. 1993) and pGSK-3b is associated with
microcyst epithelium (Kjaersgaard et al. 2011). GSK-3b
inhibition could therefore be implicated in the cystic
changes seen after lithium treatment. As COX-2 is upreg-
ulated in cortex in conditions with negative salt balance
and polyuria as, for example, induced by furosemide
(Mann et al. 2001) or lithium (Rao et al. 2005), the epi-
thelium is likely exposed to elevated concentration of
prostaglandins. The PGE2-EP4 receptor is localized in the
nephron segments injured after postnatal lithium treat-
ment (Jensen et al. 2001; Kjaersgaard et al. 2011). Activa-
tion of the EP4 receptor can lead to PI3 kinase – PKB/
Akt-mediated phosphorylation and inactivation of GSK-
3b (Fujino et al. 2002). Activation of the EP4 receptor
leads to increased formation of cyclic adenosine mono-
phosphate, which is known to be involved in cyst forma-
tion in polycystic kidney disease (Belibi et al. 2004).
Therefore, an increased formation of prostaglandins in
cortex could promote aberrant cystic epithelial changes
after lithium treatment. It was hypothesized that lithium
treatment leads to renal microcysts through COX-2 activ-
ity. To address this, lithium was administered to rats in
the sensitive postnatal “window” (postnatal days 7–34),
with and without the selective COX-2 inhibitor parecoxib.
Kidney tissue, plasma, and salt and water metabolism
were analyzed. In addition, aquaporin-2 (AQP2) protein
was followed as a differentiation marker for principal
cells.
Materials and Methods
Animals
All animal experiments conformed to the Danish national
guidelines for the care and handling of animals and to
the published guidelines from the National Institutes of
Health. Experiments were approved by the national
Danish Animal Experiments review board under The
Department of Justice (approvals no. 561-1050 [period
2005–2010] and 561-1875 [period 2010–2015]) and by
the Review Board at the Faculty of Health Science, Ani-
mal Facility, University of Southern Denmark. Animals
were housed at the Biomedical Laboratory at University
of Southern Denmark. Animals were kept at a 12:12 h
light:dark cycle and provided with free access to standard
pathogen-free rat chow (Altromin cat.log 1310, Lage,
Germany; Na+ 2 g/kg, Cl 5 g/kg) and tap water. Female
Wistar rats were used for breeding.
Series 1
Kidney tissue was stored from a published series of rats
(Kjaersgaard et al. 2011) with lithium treatment from P7
to P28 (50 mmol/kg diet).
Series 2
Litters were reduced to eight pups (males only were inves-
tigated) to ensure equal feeding. Half of the dams were
kept on standard rat chow, whereas the other half was pro-
vided with lithium-enriched chow (50 mmol/kg diet) from
postnatal day 7 (P7). Animals had free access to tap water,
isotonic saline, and a solid salt lick (100% NaCl). One half
of each litter was injected subcutaneously (SC) with Parec-
oxib (2.5 lg/g in 5 lL/g isotonic glucose twice daily) and
the other with vehicle (5 lL/g isotonic glucose twice daily)
from P10. Thus, animals were divided into four groups:
control-vehicle (CV), control-parecoxib (CP), lithium-
vehicle (LV), and lithium-parecoxib (LP). A total of 10
pups were utilized in each group. At postnatal day 29, the
adolescent rats were placed in metabolic cages (N = 2
from each of the four groups per experiment, repeated five
times). Animals had free access to water and lithium-
enriched or standard granulate chow. To avoid food con-
tamination in the urine and feces collections, diet in the
metabolic cages was administered as 1.7 mm granules.
Granules were produced from pulverized pellets dissolved
in 70% ethanol, squeezed through a sieve and dried for a
minimum of 3 h (60°C). After a run-in period of two con-
secutive days, 24 h urine was collected for baseline mea-
surements before urine concentrating ability was tested
with a bolus injection of 1-desamino-8-D-arginine vaso-
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pressin (dDAVP) (1 lg/kg SC). Urine was collected 4 and
6 h post-dDAVP treatment. On the following day animals
were anesthetized by intraperitoneal injections of sodium
pentobarbital 50 mg/kg. All rats donated at least one kid-
ney to RNA/protein measurements. Half of the rats were
exsanguinated by cardiac puncture to obtain plasma in
which case tissue was used from both kidneys for RNA/
protein. The other half of the rats donated one kidney for
protein/RNA after ligation of the renal artery. The other
kidney was then perfusion fixed. Plasma was isolated by
centrifugation. Kidneys were separated into cortex and
medulla and snap frozen in liquid nitrogen. Fixation was
through the left cardiac ventricle with 4% phosphate-buf-
fered formaldehyde.
Human kidney tissue
The nephrectomy specimen was obtained as previously
described (Kjaersgaard et al. 2012) from a 71-year-old
male patient treated with lithium for 28 years and under-
going nephrectomy due to renal cell cancer. The patient
gave informed written consent to participate, and experi-
ments were approved by the Regional Biomedical
Research Ethics Committee (S-VF-20010035).
Osmolality and electrolyte measurements
Plasma and urine osmolalities were determined by freeze-
point depression (Osmomat 030-D, Gonotec, Bie and
Berntsen and The Advanced Osmometer 3D3, Advanced
Instruments). Na+, K+, and Li+ concentrations were
determined by flame photometry (model IL 943; Instru-
mentation Laboratory, Lexington, MA).
Hormone measurements
Urinary PGE2 was measured using enzyme immunoassay
kit (Cayman, #514010). In brief, urine was used unacetylat-
ed, diluted according to pilot experiments (1:5–1:500), and
each dilution was measured in duplicate. The amount of
PGE2 in each sample is inversely proportional to the mea-
sured absorbance as the kit is competitive. To each well,
antibody specific to PGE2 and PGE2-acetylcholinesterase
(AChE) was added. These two reagents bind competitively
to the anti-mouse IgG used to coat the well. AChE reacted
with Ellman’s Reagent and this reaction, giving a yellow
color, was then measured spectrophotometrically.
Plasma renin was measured by radioimmunoassay. In
brief, plasma samples, standards, and controls were incu-
bated with substrate (enriched sheep angiotensinogen)
and primary antibody at 37°C for 24 h. The reaction was
then quenched with cold KBC buffer (0.5 mol/L Tris buf-
fer, pH 7.4 with 10 mmol/L titriplex III, 0.25 mmol/L
thiomersal, and 1 g/L albumin) before tracer (125I-angio-
tensin I, diluted 1:7 in buffer) was added and samples
were incubated overnight at 4°C. Finally, samples were
suspended in SAC-CEL (solid-phase secondary antibody
coated cellulose suspension, IDS, U.K.) and separated
using centrifugation. The reactivity of the sediment was
determined by gamma counting.
Quantitative polymerase chain reaction
Isolation of RNA from control and lithium-treated kidney
cortex and medulla was carried out using RNeasy mini kit
(Qiagen Nordic, Copenhagen, Denmark) according to
manufacturer’s protocol. RNA was quantified using Nano-
Photometer from Implen (AH Diagnostics, Aarhus V,
Denmark) and stored at 80°C. cDNA was obtained by
reverse transcription of 1 lg total RNA using the iScript
cDNA synthesis kit (Bio-Rad Laboratories, Copenhagen,
Denmark). For qPCR, duplicates of cDNA corresponding
to 50 ng of total RNA were used as template and mixed
with 10 pmol of each primer (COX-2: 5′-cgg-gat-ccg-aaa-
tgg-ctg-cag-agt-tg-3′; 5′-atg-gtg-gct-gtc-ttg-gta-3′; 331 bp;
COX-1: 5′-cgg-gat-ccg-ctg-ctg-aga-agg-gag-tt-3′; 5′-gga-
att-cgg-tgg-tac-tgt-cgt-tcc-a-3′; 188 bp; Glyceraldehyde
3-phosphate dehydrogenase (nested): 5′-ctc-atg-acc-aca-
gtc-cat-gc-3′; 5′-ttc-agc-tct-ggg-atg-acc-tt-3′; 155 bp), iQ
SYBR Green Supermix (Bio-Rad), and RNase-free water to
a total volume of 25 lL. Water and samples without
reverse transcriptase were used as negative controls. After
denaturing the mixture for 3 min at 95°C, 40 cycles were
run as follows: 30 sec of denaturing at 95°C and 45 sec of
annealing and extension at 60°C (MyIQ ICycler; Bio-Rad).
By measuring SYBR green fluorescence in each cycle,
amplification was detected. Purified PCR product was used
to generate a standard curve by plotting threshold
cycle against serial dilution of PCR product of the gene of
interest.
Western blotting
Proteins were homogenized in sucrose/imidazole buffer
([0.3 mol/L sucrose, 25 mmol/L imidazole, 1 mmol/L
ethylenediaminetetraacetic acid, pH 7.2]; right before use,
the buffer was supplemented with protease inhibitors
[0.4 mol/L pefablock and 2.1 mmol/L leupeptin] and
phosphatase inhibitors [1 mmol/L Na orthovanadate,
0.2 mol/L NaF, and 0.082 lg/lL okadaic acid]) and
quantified by the Bradford method. For western blotting,
10 lg of protein was run on a sodiumdodecyl sulfate
polyacrylamide gel electrophoresis (SDS-PAGE) gel. Each
sample was supplemented with reducing agent (NuPAGE
Sample Reducing agent; Invitrogen, Taastrup, Denmark)
and sample buffer (NuPAGE LDS Sample buffer; Invitro-
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gen) and then denatured for 5 min at 95°C before run-
ning. Proteins were transferred to an activated 0.45-lm
pore-size Immobilon-P polyvinylidene difluoride mem-
brane (Millipore, Hellerup, Denmark) in the blotting sys-
tem (XCell SureLock Mini-Cell system; Invitrogen).
Membranes were blocked with 5% nonfat milk in tris
buffered saline and tween 20 for 1 h before incubation
with primary antibody. Primary antibodies against GSK-
3b (9315, Cell Signaling [BioNordika Denmark A/S,
Glostrup, Denmark], 1:2500), pGSK-3b-s9 (9336, Cell
Signaling, 1:1000), COX-2 (sc-1747, Santa Cruz [Aarhus,
Denmark], 1:1000), COX-1 (160109, Cayman [Aarhus,
Denmark], 1:1000), AQP2 (sc-9882, Santa Cruz, 1:2000),
and b-actin (ab8227, Abcam [Cambridge, UK], 1:20000)
were used. Secondary antibodies used were P0448 and
P0449 (both 1:2000, Dako, Glostrup, Denmark). The
labeling was visualized by the enhanced chemilumini
scence plus Western Blotting Detection System (Amersham
Biosciences/GE Healthcare Europe GmbH, Brondby,
Denmark).
Immunohistochemistry
Tissue sections were deparaffinized in Tissue Clear and
rehydrated in a graded series of ethanol (99–70%). Antigen
retrieval was carried out by boiling for 20 min in 19 Tar-
get Retrieval Solution Citrate buffer (Dako). Primary anti-
bodies against COX-2 (sc-1747, Santa Cruz, 1:500), COX-1
(160109 Cayman, 1:500), and AQP2 (sc-9882, Santa Cruz,
1:50) were used. The antigen–antibody complex was visual-
ized by horseradish peroxidase-conjugated secondary anti-
body (EnVision ready-to-use polymer, P0449 1:1000 or
1:200, Dako). After washing, the labeling was visualized
with 3,3′-diaminobenzidine (DAB+, K3468, Dako). The
reaction was quenched with water and the slides were
counterstained with Mayer’s Hematoxylin for 2 min. For
visualization of tissue damage, deparaffinized sections were
stained with hematoxylin and eosin, rehydrated, and
mounted.
Statistics
All values are presented as means  standard error of
means (SEM). Two groups were compared by unpaired
Student’s t-test. Multiple comparisons were analyzed with
two-way analysis of variance (ANOVA) followed by Bon-
ferroni’s multiple comparison test or with the nonpara-
metric Kruskal–Wallis followed by Dunn’s multiple
comparisons test. When necessary, data were log trans-
formed to allow for parametric testing. P < 0.05 (two-
sided value, *) was considered significant. P < 0.01 was
designated **. All statistical tests were performed using
Graph Pad Prism 5.01.
Results
Effect of lithium and parecoxib treatment
on kidney tissue COX-2 abundance
Kidney tissue from rats treated with lithium from P7–28
(series 1) showed no significant difference in the level of
COX-2 mRNA, whereas COX-2 protein abundance was
increased significantly in cortex (Fig. 1A). COX-2 was not
changed in medulla (Fig. 1B). Lithium treatment in series
2 (P7–P34) led to a significant increase in COX-2 protein
level compared to control (Fig. 1C). Parecoxib treatment
did not alter COX-2 protein abundance compared to
vehicle in lithium-treated rats and in control rats
(Fig. 1C). The abundance of b-actin protein did not
change significantly with any condition and was used
accordingly to normalize for loading and quality.
Effect of COX-2 inhibition on lithium-
induced kidney tissue
Lithium treatment P7–34 led to structural kidney tissue
changes (Fig. 2A and B). The kidney cortex displayed
dilated and microcystic tubules associated with medullary
rays, whereas the outer and inner medulla did not exhibit
dilatations or cysts. The microcysts appeared to originate
from collecting ducts (“*” in Fig. 2A and B). By simple
inspection, treatment with the selective COX-2 inhibitor
parecoxib did not reverse or attenuate the lithium-
induced microcystic tissue alterations (Fig. 2A – vehicle
and B – parecoxib). Parecoxib alone had no detectable
effect on kidney morphology (not shown). Immunohisto-
chemical labeling of control kidneys for COX-2 showed
distinct signals associated with the TAL and in particular
the macula densa (Fig. 2C and D). Parecoxib treatment
did not alter the distribution of COX-2 (Fig. 2C and D)
compared to control. Lithium treatment with or without
parecoxib did not alter the association of COX-2 with the
cortical loop of Henle (Fig. 2E and F) compared to con-
trol, and there were no major changes in staining inten-
sity (Fig. 2C and D vs. E and F). Dilated tubules and
regular microcysts in cortical medullary rays were not im-
munopositive for COX-2 (Fig. 2E and F).
Effect of COX-2 inhibition on somatic
growth and plasma parameters
Rats treated with lithium P7–34 displayed reduced
somatic and kidney growth, but relative kidney hypertro-
phy with increased kidney weight/body weight ratio com-
pared to control rats (Table 1). Parecoxib treatment had
no effect on growth in either the control or the lithium
group. Lithium reached concentrations of ~1 mmol/L in
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plasma and there was no difference in plasma lithium
concentration between LV and LP groups (Table 1). Lith-
ium was not detectable in plasma from controls
(Table 1). Plasma osmolality tended to be higher in lith-
ium-treated rats, however, this only reached a significant
level in the parecoxib–lithium group (Table 1). Plasma
sodium concentration was higher in lithium-treated
animals compared to the other three groups (Table 1).
Hematocrit and plasma K+ concentration were not signif-
icantly different between groups (Table 1). Lithium treat-
ment increased plasma renin concentration significantly
(Table 1) and this increase was blocked by parecoxib
(Table 1). Cortical tissue PGE2 concentrations were not
different between the four groups (Table 1).
Effect of COX-2 inhibition on lithium-
induced cell proliferation and GSK-3b
phosphorylation
Lithium treatment led to a significant increase in protein
abundance of the mitosis marker proliferating cell nuclear
antigen (PCNA) in cortex compared to the CP group but
not vehicle-control group (Fig. 3A). PCNA abundance in
medulla was not different between the groups (not
shown). Parecoxib treatment did not alter cortical PCNA
abundance in control or lithium-treated group (Fig. 3A).
Lithium treatment led to a significant increase in the
abundance of serine 9 phosphorylated inactive GSK-3b
protein in kidney cortex compared to CP group but not
C
A B
Figure 1. Effect of lithium treatment on COX-2 mRNA and protein level. (A) Effect of lithium treatment through postnatal days 7–28 on
kidney cortex COX-2 mRNA level (left panel) and cortex COX-2 protein abundance (right panel and immunoblottings shown above). Values are
mean  SEM, * P < 0.05 (n = 6 for control, n = 12 for lithium treatment). (B) Effect of lithium treatment P7–P28 on kidney medulla COX-2
mRNA level (left panel) and COX-2 protein abundance (right panel, immunoblottings shown above). Values are mean  SEM, * P < 0.05
(n = 6 for control, n = 12 for lithium treatment). (C) Protein abundance of COX-2 in kidney cortex as assessed by western blotting of tissue
from rats treated with vehicle (control-vehicle, CV); parecoxib, 5 mg/kg per day (control-parecoxib, CP); lithium and vehicle (Li-vehicle, LV); and
lithium and parecoxib, 5 mg/kg per day (Li-parecoxib, LP). Data are presented as means  SEM, *P < 0.05; n = 5 in all groups.
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the CV group (Fig. 3B). Parecoxib treatment did not sig-
nificantly alter the level of pGSK-3b-s9 compared to con-
trol and to lithium (Fig. 3B). Abundance of total GSK-3b
protein was not significantly altered by lithium treatment,
by parecoxib treatment, or by combination of the two
(Fig. 3B).
Effect of COX-2 inhibition on urine
concentration ability after lithium
treatment
Diet intake and feces excretion were significantly lower in
lithium-treated animals, whereas sodium excretion in
urine was higher in lithium-treated rats with no effect of
parecoxib (Table 2). Urine flow and water intake were
significantly and markedly increased by lithium treatment
and was associated with a lower basal urine osmolality;
none of these baseline parameters was affected by parec-
oxib (Table 2 and Fig. 4A). At baseline, urinary PGE2
excretion was not significantly different between the four
groups (Table 2). Control animals increased significantly
urine osmolality compared to baseline 4 and 6 h after a
dDAVP bolus injection with no additional effect of parec-
oxib administration (Fig. 4A). Urine flow was decreased
by dDAVP compared to baseline (Table 2). Rats treated
with lithium displayed lower urine osmolality at all time
points compared to control (Fig. 4A). Lithium-treated
rats increased urine osmolality 4 h after dDAVP injection
compared to baseline, and the D osmolality increase was
similar between groups (Fig. 4B). Absolute urine osmolal-
LPCP LVCV
*
*
*
G
G
D E F
BA
C
Figure 2. Effect of lithium with and without a COX-2 inhibitor on kidney morphology and COX-2 localization. (A and B) Hematoxylin and
eosin stained kidney sections from rats treated with lithium (P7–P34) without (A) and with parecoxib (B, 5 mg/kg per day, P10–P34). Parecoxib
treatment itself had no visible effect on kidney morphology compared to vehicle (not shown). Lithium-treated kidneys displayed tubular
dilatations and microcysts (*) in medullary rays (A) which were not altered visibly by parecoxib (B). “G” - glomerulus four different kidneys were
inspected for each group. Scale bar = 200 lm. (C–F), COX-2 labeling was located primarily to the macula densa region in all four groups. The
dilated tubules and microcysts in no case were COX-2 positive (E and F). Scale bar = 50 lm.
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ity value was significantly higher after parecoxib treatment
after 4 h (Fig. 4A). Sodium excretion was significantly
lowered by parecoxib 4 h after dDAVP in lithium-treated
rats (Table 2). After 6 h, urine osmolality had returned to
the low baseline level in lithium groups with no effect of
parecoxib (Fig. 4A) and thus D osmolality was signifi-
cantly lower compared to control and control-parecoxib
rats (Fig. 4C). Sodium excretion was similar in all four
groups 6 h after dDAVP.
In lithium-treated rats, urine flow 4 h after dDAVP
was markedly lower compared to lithium-treated rats at
baseline (Table 2) and only dDAVP-treated, LV rats had
significantly higher diuresis compared to control rats
(Table 2). Thus, parecoxib significantly lowered urine
flow in dDAVP-challenged, lithium-treated compared to
LV rats (Table 2).
In lithium-treated animals, the urine flow had returned
to high baseline levels 6 h after dDAVP injection, whereas
control animals still had a lower urine flow at this time
point (Table 2).
Effect of lithium and COX-2 inhibition on AQP2
Next, it was addressed whether AQP2 protein was affected
by lithium. Western immunoblotting for AQP2 in vehicle
and lithium-treated rat kidney cortex homogenates dis-
played a significantly reduced level of both glycosylated
AQP2 (not shown) and nonglycosylated AQP2 protein
(Fig. 5A) in response to lithium treatment. There was no
effect of parecoxib on the lithium-induced suppression of
AQP2 protein level (Fig. 5A). Immunohistochemical
labeling of kidney sections for AQP2 showed more
widespread localization and more intense immunoreactive
protein in control animals compared to lithium-treated
animals (Fig. 5B and D). In lithium-treated animals, there
was a markedly lower number of AQP2-positive cells in
the cortical collecting ducts and most cells associated with
regular cysts were AQP2 negative (Fig. 5D and E).
Effect of lithium treatment on COX-1
abundance in rat and human kidney
Lithium treatment significantly increased renal cortical
tissue level of COX-1 mRNA and protein in rats
(Fig. 6A). Parecoxib had no effect on COX-1 mRNA and
protein abundance (Fig. 6A). In control rat kidneys,
COX-1 was associated with subsets of cells in cortical col-
lecting ducts (Fig. 6B), likely principal cells, as COX-1
was associated with all cells along the inner medullary
collecting duct and with medullary interstitial cells (not
shown). The microcysts and dilated collecting ducts in
renal cortex from lithium-treated rats were strongly im-
munopositive for COX-1 (Fig. 6C and E). In the absence
of primary antibody, no labeling was observed (Fig. 6D).
Histological sections of a nephrectomy kidney from a
patient treated with lithium for 28 years revealed multiple
microcysts and larger lacunar areas lined by epithelium
(Fig. 6F). Cysts were observed in cortex (Fig. 6F) but not
in medulla (not shown). Focal interstitial fibrosis was seen
in the kidney, especially in cortical areas with tubular
atrophy. Both normally appearing cortical collecting ducts
and the cystic epithelium were immunopositive for COX-
1 (Fig. 6F and G). Cyst epithelium was uniformly positive
for COX-1, whereas in the absence of primary antibody,
no reaction was observed by secondary antibody
(Fig. 6H).
Table 1. Weight and plasma data at euthanasia.
CV CP LV LP
Body weight (g) 118.3  2.4 111.8  2 52.2  2.7* 49.7  2.2*
Kidney weight (mg) 1121.0  20.4 1186.8  50.4 764.0  37.8* 745.25  3.7*
Kidney weight/body weight (mg/g) 9.9  0.1 10.6  0.3 15  0.9* 14.5  1.6*
Plasma osmolality (mOsm/kg H2O) 294  0.6 294  2.2 310  3.4* 313  3.6*
Plasma [Na+] (mmol/L) 137.2  1.0 137.9  0.7 146.4  2.0# 145.0  2.7
Plasma [K+] (mmol/L) 5.6  0.3 5.5  0.3 5.3  0.2 5.5  0.6
Plasma [Li+] (mmol/L) ND ND 0.95  0.14 1.29  0.13
Hematocrit (%) 34.8  0.8 35.2  0.8 32.2  1.0 31.8  1.2
Plasma renin ng (ANG I/L/h) 2442  388 3242  385 7483  894# 6799  3343
Cortical PGE2 (pg/mg protein) 22.5  1.5 19.2  1.3 32.1  5.3 23.7  4.8
Because plasma was not sampled for rats used for fixation, n = 9–10 for body weight and cortical PGE2 data, while all plasma data are n = 4–5.
Data have been analyzed with one-way ANOVA followed by Bonferroni’s multiple comparisons test. Data are presented as means  SEM. Small
groups (n < 5) were analyzed with nonparametric Kruskal–Wallis test followed by Dunn’s multiple comparisons test. ND, not determined.
*P < 0.05 compared to the CV and CP groups.
#P < 0.05 CV and CP versus LV.
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Discussion
This study shows lithium-induced somatic growth retar-
dation with relative kidney hypertrophy, epithelial cell
proliferation, and cortical microcysts with significantly
increased cortical COX-2 protein associated with loop of
Henle and macula densa. After lithium treatment, rats
displayed AQP2 downregulation associated with NDI
and reduced urine concentrating ability; increased
inactive phopho-GSK3b and increased COX-1 protein
abundance in cortical cystic collecting duct epithelium.
While continuous COX-2 inhibitor treatment transiently
and marginally improved dDAVP-induced urine concen-
trating ability and lowered plasma renin concentration
and improved sodium retention in lithium-treated rats,
it did not alter microcyst formation, AQP2 downregula-
tion, inactivating GSK-3b phosphorylation, and COX-1
upregulation. Thus, enhanced COX-2 activity is not
likely to be the primary cause for microcysts or diabetes
insipidus in the chronic, adolescent rat model of lithium
nephropathy. The spatial colocalization with cyst epithe-
lium and upregulation of COX-1 mRNA and protein
abundance in both rat and human kidneys suggest that
focus should be on this isoform in relation to potential
prostaglandin-mediated effects on tubular dilatation/mi-
crocysts.
The modest increase in COX-2 protein level and
restricted distribution of COX-2 in TAL/MD segment are
similar to previous data from adult rat kidney (Kotnik
et al. 2005). The stimulation of COX-2 by lithium is
likely indirect, as no data support that apical lithium
uptake occurs in TAL. On the other hand, a low transepi-
thelial transport rate of NaCl in TAL/MD cells, caused by,
for example, low dietary NaCl intake or diuretics is a pri-
mary stimulus for COX-2 (Harris et al. 1994; Jensen and
Kurtz 1997; Yang et al. 1998). The elevated plasma Na+
concentration shows loss of water in excess of sodium.
With the moderate stimulation of renin release, extracel-
lular volume of the lithium rats is not severely depleted.
A
B
Figure 3. Effect of lithium treatment with and without a COX-2
inhibitor on cell proliferation and glycogen synthase kinase-3b
phosphorylation. (A) Western blotting (upper panel) of kidney
cortex tissue homogenates for proliferating cell nuclear antigen
(PCNA), a marker of mitosis, and densitometric evaluation of gels
(diagram). Values were normalized to b-actin protein abundance.
Lithium increased PCNA protein abundance with no effect of
parecoxib treatment. Data were analyzed with two-way ANOVA
followed by Bonferroni’s multiple comparisons test. The columns
show mean values SEM, *P < 0.05; n = 5 in all groups. (B)
Western blotting of kidney cortex tissue homogenates for phospho-
serine 9 (pGSK-3b-s9) and total GSK-3b (upper panel) and
densitometric evaluation of gels (diagrams). For samples showing
double bands, the upper band was chosen for quantification
according to the predicted size of the protein. Lithium treatment
significantly increased the abundance of pGSK-3b-s9. No effect of
parecoxib treatment was seen. The abundance of total GSK-3b was
not significantly altered between any of the four experimental
groups. Data were analyzed with two-way ANOVA followed by
Bonferroni’s multiple comparisons test. Data are presented as
means  SEM, *P < 0.05; n = 5 in all each group.
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Salt supplementation in the present model is necessary to
maintain survival, and the support of ECV through the
salt lick is the likely cause for the very modest stimulation
of renin, cortical COX-2, and PGE2 urine excretion
(Christensen and Ottosen 1983; Kjaersgaard et al. 2011).
This is also a likely explanation as to why parecoxib had
no effect on urine PGE2 excretion. The polyuria may have
contributed to the significant growth retardation, but rats
ate less of the lithium-containing food pellet per gram
weight. Growth retardation is a typical feature of
lithium-treated rodent models and is not likely to cause
microcysts and polyuria. Growth impairment is fully
reversible; when lithium is withdrawn, rats displayed a
rapid catch-up growth and after 4 weeks without lithium
on standard rat chow (postnatal day 70), their weight and
baseline renal parameters were normal compared to con-
trols (Kjaersgaard et al. 2012). In mice, COX-2 expression
is increased after 2 weeks of lithium treatment (Rao et al.
2005; Yoshioka et al. 2009). Increased COX-2 expression
after lithium treatment has been shown to correlate with
Table 2. Urine parameters in rats treated with lithium and/or parecoxib before, during, and after dDAVP injection.
Baseline CV CP LV LP
Diet intake (g/100 g per 24 h) 16.5  0.2 16.1  0.3 11.6  0.8* 12.2  1.0*
Feces excretion (g/100 g per 24 h) 9.7 10.9 6.5* 4.7*
Water intake (mL/100 g per 24 h) 25.2 24.9 62.9* 54.2*
Urine flow (mL/100 g per 24 h) 10 9 42.8* 35.4*
Urinary sodium excretion (mmol/100 g per 24 h) 0.76  0.04 0.76  0.04 1.08  0.05* 1.02  0.05*
Urine PGE2 (ng/100 g per 24 h) 31.9  4.2 79.7  29.2 26.7  3.0 25.2  2.5
dDAVP + 4 h
Urine flow (mL/100 g per 24 h) 4.3 4.7 19.1* 9
Urinary sodium excretion (mmol/100 g per 24 h) 0.62  0.06 0.54  0.04 1.01  0.21 0.28  0.05#
dDAVP + 6 h
Urine flow (mL/100 g per 24 h) 5.6 5.7 31.4* 38.8*
Urinary sodium excretion (mmol/100 g per 24 h) 1.33  0.10 1.31  0.09 0.94  0.11 1.22  0.18
Data have been analyzed with two-way ANOVA followed by Bonferroni’s multiple comparisons test. Data are presented as means  SEM.
When no standard error is shown data have been log transformed and the geometric mean is shown. Data that did not achieve normal distri-
bution were analyzed with the nonparametric Kruskal–Wallis test followed by Dunn’s multiple comparisons test.
*P < 0.05 compared to the CV and CP groups.
#P < 0.05 LP versus LV. N = 10 unless otherwise stated.
B CA
Figure 4. Effect of a COX-2 inhibitor on lithium-induced polyuria. (A) At baseline, urine osmolality was significantly higher in control animals
compared to lithium-treated animals. Upon stimulation with dDAVP, all animals increased urinary osmolality, but lithium-treated animals were
not able to sustain the increase at 6 h after dDAVP injection. Lithium-parecoxib–treated animals had a significantly higher urine osmolality 4 h
after dDAVP injection as compared with lithium-vehicle–treated animals indicated by *. Control and lithium-treated groups were analyzed
separately by two-way ANOVA to avoid interaction followed by Bonferroni’s multiple comparisons test. The effect of dDAVP was significant in
both groups, symbolized by $. *Significant difference between lithium-vehicle and lithium-parecoxib groups at dDAVP + 4 h, also analyzed by
two-way ANOVA. (B) The increase in urinary osmolality (D osmolality) was similar in the four groups 4 h after dDAVP injection compared to the
basal level. Data are analyzed with two-way ANOVA followed by Bonferroni’s multiple comparisons test. (C) The increase in urinary osmolality
was abolished 6 h after dDAVP injection in lithium-treated animals. Control animals maintained an increased urinary osmolality compared to
baseline and significantly larger increase (D osmolality) than in lithium-treated animals. Data are analyzed with two-way ANOVA followed by
Bonferroni’s multiple comparisons test. **P < 0.01 Li groups compared to control-vehicle and control-parecoxib. Data are presented as
means  SEM; n = 10 in all groups.
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Figure 5. Effect of lithium treatment with and without a COX-2 inhibitor on AQP2 abundance and localization. (A) The panels show result of
western blotting of kidney cortex tissue homogenates for aquaporin-2 (AQP2, upper panel) and densitometric evaluation of gels (diagram).
Values were normalized to b-actin protein abundance. Lithium significantly suppressed the protein abundance of AQP2 with no effect of
parecoxib treatment. Columns display mean  SEM, *P < 0.05, n = 6. (B–E) Immunohistochemical labeling of rat kidney sections for AQP2
showed decreased labeling in both lithium-treated groups (D and E) compared to vehicle and parecoxib-treated groups (B, C). Parecoxib had no
discernible effect on AQP2 signal distribution or intensity (C and E vs. B and D). Dilated tubules and microcysts in lithium-treated kidneys
showed single AQP2 immunopositive cells and cell clusters, but the majority of cells associated with dilatations and cysts were not positive for
AQP2 (D and E). Scale bar = 50 lm. Kidney sections from four animals in each group were analyzed. Scale bar = 200 lm.
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Figure 6. Effect of lithium treatment and COX-2 inhibition on COX-1 abundance and localization in rat and human kidney. (A) COX-1 mRNA
expression (left panel) and protein abundance (right panel) in kidney cortex tissue homogenates. Western immunoblotting for COX-1 with rat
kidney cortex homogenate is shown above the diagram. COX-1 has a molecular weight ~72 kDa and a product at 100 kDa was regularly
observed and considered as unspecific. COX-1 mRNA level and protein abundance were significantly upregulated by lithium with no effect of
parecoxib treatment. Columns display mean  SEM, *P < 0.05 between the groups marked by lines (n = 6). (B–E) Immunhistochemical staining
of kidney section from control rat (B) and rat treated with lithium (C) for cyclooxygenase-1 (COX-1). Cortex is shown. Negative control with
omission of primary antibody is seen in (D). At larger magnification of lithium-treated rat kidney section (E), microcystic and dilated epithelium
is COX-1 positive and in control kidney, immunoreactive COX-1 is associated with collecting ducts in cortex (B) and medulla (not shown). Scale
bar = 200 lm in (B–D) and 50 lm in (E). (F–H) Immunohistochemical staining of kidney sections for COX-1 from a human nephrectomy
specimen removed from a patient treated with lithium for 28 years and suffering from renal clear cell cancer. At low magnification, the
sections displayed multiple larger and smaller cysts separated by normally appearing tissue and glomeruli (F). Medulla appeared normal (not
shown). Immunopositive reaction was associated with cysts and collecting ducts, whereas the major part of the cortical tissue with proximal
convoluted tubules was negative (F and G). At higher magnification, both large and small cysts displayed labeling associated with the epithelial
cells that lined the cysts (G). In the absence of primary antibody, the tissue exhibited no reaction (H). Scale bar = 200 lm in (F and H) and
50 lm in (G).
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an increased urinary PGE2 excretion (Kotnik et al. 2005;
Rao et al. 2005; Jia et al. 2009) and an effect of COX-2
inhibitors (Rao et al. 2005; Kim et al. 2008). While effects
on diuresis and AQP2 by lithium were similar to the
present observations, the fold change of COX-2 expression
in the mouse models was much larger compared to the
present rat model which could be due to the lack of salt
substitution and larger extracellular volume depletion. In
this study, lithium-mediated downregulation of AQP2
abundance was confirmed (Marples et al. 1995; Korteno-
even et al. 2012) and no rescue was observed using a
COX-2 inhibitor. This supports the observation by
Kortenoeven et al. (2012) that the Li+-mediated AQP2
downregulation is independent of COX-2. Undisputedly,
in situations with marked stimulation of renal prostaglan-
din formation, as measured by the surrogate marker of
urine excretion (Rao et al. 2005; Kim et al. 2008), a
contribution of COX-2 to polyuria and AQP2 downregu-
lation is revealed by pharmacological inhibitors (Norreg-
aard et al. 2007). Similar to these observations, in this
study, a transiently increased urine osmolality and reduc-
tion in urine flow, plasma renin, and sodium excretion
by COX-2 inhibition were observed in the lithium-treated
group. These findings show that parecoxib reached its tar-
get as previously seen with this dose (Stubbe et al. 2003;
Norregaard et al. 2005). As COX-1 is the predominant
isoform in collecting ducts and COX-1 protein abundance
was significantly increased in the present rat model, it is
likely that COX-1 activity masks the effects of COX-2
inhibition and thus explains the present observation of
similar PGE2 urine excretion in all four groups (Campean
et al. 2003). In this study, the dose of parecoxib (5 mg/kg
per day) was identical to previous studies in both young
and adult animals (Stubbe et al. 2003, 2007; Norregaard
et al. 2005). Parecoxib is a prodrug of valdecoxib, which
is a potent and selective COX-2 inhibitor with ED50 =
0.03 mg/kg (Gierse et al. 2005). The same dose and route
of administration has been used with effect in adult
Munich-Wistar rats (Norregaard et al. 2005) and in
Sprague–Dawley rats during kidney development (Stubbe
et al. 2003). In the rat study by Kim et al. (2008), a
COX-2 blocker improved baseline diuresis, but was used
at 40 mg/kg. At this dose, it is likely also to affect COX-1
and COX abundances in kidney tissue were not reported
(Kim et al. 2008). It cannot be ruled out that the benefi-
cial effects in this study could be caused by COX-1-medi-
ated effects and/or a decrease in GFR also could
contribute.
Disruption of aENaC prevents lithium-induced poly-
uria in mice (Christensen et al. 2011). ENaC is colocal-
ized with dilations/microcysts, mitotic activity and
increased expression of pGSK-3b-s9 in collecting duct
after lithium treatment (Kjaersgaard et al. 2012). As no
effect of the COX-2 inhibitor on these parameters was
discovered and COX-2 was not colocalized with the
lesions, the cystic change is likely caused by apical entry
of lithium and not by paracrine action of COX-2. Poly-
uria per se is not likely to have caused the lesions, as in
adult, lithium-treated animals, inhibition of polyuria with
large doses of vasopressin does not abolish the lithium-
induced kidney injury (Ottosen et al. 1988). Polyuria by
other causes, for example, deletion of sodium potassium
2-chloride co-transporter or renal outer medullary potas-
sium channel causes a hydronephrosis-like phenotype
with papillary atrophy and cortical thinning that does not
mimic the present cortical microcysts induced by lithium
(Takahashi et al. 2000; Lorenz et al. 2002). Similar data
have been obtained in mice with inducible AQP2 knock-
down (“inducible diabetes insipidus”) that exhibit only
mildly dilated cortical and medullary collecting ducts, but
no microcysts as seen with lithium (Yang et al. 2006). In
summary, lithium treatment of NaCl-supplemented male
rats immediately before and after weaning leads to four
times higher diuresis, significant dilatations, and micro-
cysts in cortical collecting ducts and marginal stimulation
of COX-2 abundance in macula densa/loop of Henle seg-
ment with no change in PGE2 excretion. Concomitant
treatment with lithium and a COX-2 inhibitor yielded a
transient and minor improvement in dDAVP-induced
urine concentration, whereas it did not attenuate micro-
cyst formation, GSK3b inactivation, and cell proliferation.
It is concluded that COX-2 activity is not responsible for
cortical collecting duct cell proliferation and microcysts
during chronic lithium treatment.
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